Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG‐asparaginase.
- Resource Type
- Article
- Authors
- Goursaud, Laure; Berthon, Celine; Quesnel, Bruno
- Source
- British Journal of Haematology. Feb2023, Vol. 200 Issue 4, pe37-e39. 3p.
- Subject
- *LYMPHOBLASTIC leukemia
*ACUTE leukemia
*CELLULAR therapy
*PULMONARY aspergillosis
*FEBRILE neutropenia
*VENETOCLAX
*HEMATOPOIETIC stem cell transplantation
- Language
- ISSN
- 0007-1048
Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase Keywords: cell therapy; leukaemia; PEG-asparaginase; refractory; venetoclax EN cell therapy leukaemia PEG-asparaginase refractory venetoclax e37 e39 3 02/07/23 20230215 NES 230215 Relapse is still the main cause of treatment failure in adult patients with acute lymphoblastic leukaemia (ALL). Six patients (75%) achieved complete remission (CR) after one VEN/PEG-ASP cycle and were successfully bridged to cell therapy (second allo-HSCT or donor lymphocyte infusion for three patients and CD19 CAR-T cell therapy for three patients). [Extracted from the article]